Hematology/Oncology

Top Story

Extent of lymphadenectomy may not influence survival in esophageal cancer

September 3, 2015

The number of lymph nodes removed during lymphadenectomy may not influence 5-year all-cause or disease-specific survival among patients with esophageal cancer, according to the results of a cohort study.

These study findings diverge from the current clinical practice guidelines, according to the researchers. Because metastatic lymph nodes are the strongest known prognostic factors, it had been believed that extensive lymphadenectomy improved survival outcomes.

In the Journals

Simulation model provides more accurate estimate of cancer progression in Barrett's esophagus

September 3, 2015
Simulation modeling revealed that the lower estimates of the rate of progression from Barrett’s esophagus to esophageal adenocarcinoma from population-based…
In the Journals

Imetelstat demonstrates safety, efficacy for essential thrombocythemia

September 3, 2015
Patients with essential thrombocythemia who did not respond to or had unacceptable side effects from previous therapies experienced rapid and durable hematologic and…

Novartis receives EU approval for combination treatment of metastatic melanoma

September 3, 2015
Novartis has received European Commission approval for the combination of Tafinlar and Mekinist to treat metastatic melanoma with a BRAF V600 mutation, according to a…
Ahmedin Jemal, DVM, PhD In the Journals

Contralateral prophylactic mastectomy incidence increases among men with breast cancer

September 3, 2015
The use of contralateral prophylactic mastectomy has increased among men diagnosed with unilateral breast cancer, according to study results published in JAMA
More News Headlines »
CME
Hematology Oncology Case Consults

The Patient with Pancreatic Cancer

No commercial support for this activity.

Pancreatic cancer only accounts for 3% of cancer cases, but it is the fourth leading cause of cancer-related death…
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Updates in Immunotherapy – Philadelphia 2015

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »
morganatic-roan morganatic-roan